Measurement of Intestinal Permeability in Intensive Care Patients With Single or Multiple
Multivisceral failure syndrome (MVFS) in humans is associated with a very high risk of mortality, ranging between 30 and 50%. This syndrome is associated with significant systemic inflammation and a high risk of bacteremia, the origin of which is not always identified. Among the possible causes of bacteremia, digestive
| Condition(s) | Multivisceral Failure Syndrome, Monovisceral Failure, Infection in ICU |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Multivisceral failure syndrome (MVFS) in humans is associated with a very high risk of mortality, ranging between 30 and 50%. This syndrome is associated with significant systemic inflammation and a high risk of bacteremia, the origin of which is not always identified. Among the possible causes of bacteremia, digestive translocation is the most probable but has not been formally proven to date. This translocation is made possible by the numerous cellular and metabolic alterations secondary to MVFS, which can lead to increased intestinal barrier permeability. Intestinal permeability is currently not systematically evaluated in clinical practice in humans. This increased intestinal permeability, associated with the presence of inflammatory markers and a septic state, has been studied in seve |
| Who can participate | Inclusion Criteria: Patient with single organ failure, secondary to sepsis, hospitalized in intensive care for a foreseeable duration of \> 48 hours * SAPS2 between 20 and 40 at the sixth hour after the diagnosis of organ failure. * Consent from the patient or their trusted person. * Affiliation to a social security system. * Functional digestive tract and possible feeding (per os or via a nasogastric tube whose indication was determined independently of the study's needs). Second group of patients with multi-organ failure: * Multi-organ failure syndrome with at least 2 organ failures, secondary to sepsis. * SAPS2 between 60 and 80 at the sixth hour after the diagnosis of organ failure. * Consent from the patient or their trusted person. * Affiliation to a social security system. * Functio |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Direction Centrale du Service de Santé des Armées |
| Locations | Vincennes, France |
| Start date | 2025-02-20 |
| NCT ID | NCT06845865 |
| Official listing | https://clinicaltrials.gov/study/NCT06845865 |